Suppr超能文献

舍吲哚与其他非典型抗精神病药物治疗精神分裂症的比较。

Sertindole versus other atypical antipsychotics for schizophrenia.

作者信息

Komossa Katja, Rummel-Kluge Christine, Hunger Heike, Schwarz Sandra, Schmidt Franziska, Lewis Ruth, Kissling Werner, Leucht Stefan

机构信息

Klinik und Poliklinik für Psychiatrie und Psychotherapie, Technische Universität München Klinikum rechts der Isar, Moehlstrasse 26, München, Germany, 81675.

出版信息

Cochrane Database Syst Rev. 2009 Apr 15(2):CD006752. doi: 10.1002/14651858.CD006752.pub2.

Abstract

BACKGROUND

In many countries of the industrialised world second generation (atypical) antipsychotics have become the first line drug treatment for people with schizophrenia. The question as to whether and, if so, how much the effects of the various second generation antipsychotics differ is a matter of debate.

OBJECTIVES

To evaluate the effects of sertindole compared with other second generation antipsychotics for people with schizophrenia and schizophrenia-like psychosis.

SEARCH STRATEGY

We searched the Cochrane Schizophrenia Group Trials Register (April 2007) and ClinicalTrials.gov (February 2009).

SELECTION CRITERIA

We included all randomised trials comparing oral sertindole with oral forms of amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychosis.

DATA COLLECTION AND ANALYSIS

We extracted data independently. For dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. For continuous data, we calculated weighted mean differences (WMD) again based on a random-effects model.

MAIN RESULTS

The review currently includes two short-term low-quality randomised trials (total n=508) both comparing sertindole with risperidone. One third of participants left the studies early (2 RCTs, n=504, RR 1.23 CI 0.94 to 1.60). There was no difference in efficacy (2 RCTs, n=493, WMD PANSS total change from baseline 1.98 CI -8.24 to 12.20). Compared with relatively high doses of risperidone (between 4 and 12 mg/day), sertindole produced significantly less akathisia and parkinsonism (1 RCT, n=321, RR 0.24 CI 0.09 to 0.69, NNT 14, CI 8 to 100). Sertindole produced more cardiac effects (2 RCTs, n=508, RR QTc prolongation 4.86 CI 1.94 to 12.18), weight change (2 RCTs, n=328, WMD 0.99 CI 0.12 to 1.86) and male sexual dysfunction (2 RCTs, n=437, RR 2.90 CI 1.32 to 6.35, NNH 13 CI 8 to 33).

AUTHORS' CONCLUSIONS: Sertindole may induce fewer movement disorders, but more cardiac effects, weight change and male sexual dysfunction than risperidone. However these data are based on only two studies and are too limited to allow firm conclusions. Nothing can be said about the effects of sertindole compared with second generation antipsychotics other than risperidone. There are several relevant trials underway or completed and about to report.

摘要

背景

在许多工业化国家,第二代(非典型)抗精神病药物已成为精神分裂症患者的一线药物治疗。各种第二代抗精神病药物的效果是否存在差异以及差异程度如何,这一问题仍存在争议。

目的

评估与其他第二代抗精神病药物相比,舍吲哚对精神分裂症及精神分裂症样精神病患者的疗效。

检索策略

我们检索了Cochrane精神分裂症研究组试验注册库(2007年4月)和ClinicalTrials.gov(2009年2月)。

入选标准

我们纳入了所有将口服舍吲哚与口服氨磺必利、阿立哌唑、氯氮平、奥氮平、喹硫平、利培酮、齐拉西酮或佐替平用于精神分裂症或精神分裂症样精神病患者的随机试验。

数据收集与分析

我们独立提取数据。对于二分数据,我们基于意向性分析,采用随机效应模型计算相对风险(RR)及其95%置信区间(CI)。对于连续数据,我们同样基于随机效应模型计算加权平均差(WMD)。

主要结果

本综述目前纳入了两项短期低质量随机试验(共508例),均为舍吲哚与利培酮的比较试验。三分之一的参与者提前退出研究(2项随机对照试验[n = 504],RR 1.23,CI 0.94至1.60)。疗效方面无差异(2项随机对照试验[n = 493],WMD 阳性和阴性症状量表总分较基线的变化 1.98,CI -8.24至12.20)。与相对高剂量的利培酮(4至12毫克/天)相比,舍吲哚引起的静坐不能和帕金森综合征明显更少(1项随机对照试验[n = 321],RR 0.24,CI 0.09至0.69,需治疗人数14,CI 8至100)。舍吲哚导致更多的心脏效应(2项随机对照试验[n = 508],RR QTc延长 4.86,CI 1.94至12.18)、体重变化(2项随机对照试验[n = 328],WMD 0.99,CI 0.12至1.

相似文献

2
Sertindole for schizophrenia.用于治疗精神分裂症的舍吲哚。
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.
7
New generation antipsychotics for first episode schizophrenia.用于首发精神分裂症的新一代抗精神病药物。
Cochrane Database Syst Rev. 2003;2003(4):CD004410. doi: 10.1002/14651858.CD004410.
8
Quetiapine for schizophrenia.喹硫平用于治疗精神分裂症。
Cochrane Database Syst Rev. 2004;2004(2):CD000967. doi: 10.1002/14651858.CD000967.pub2.
9
Aripiprazole for schizophrenia.阿立哌唑用于治疗精神分裂症。
Cochrane Database Syst Rev. 2006 Apr 19;2006(2):CD004578. doi: 10.1002/14651858.CD004578.pub3.
10
Risperidone versus olanzapine for schizophrenia.利培酮与奥氮平治疗精神分裂症的比较。
Cochrane Database Syst Rev. 2006 Apr 19(2):CD005237. doi: 10.1002/14651858.CD005237.pub2.

引用本文的文献

3
Risperidone versus placebo for schizophrenia.利培酮与安慰剂治疗精神分裂症的比较。
Cochrane Database Syst Rev. 2016 Dec 15;12(12):CD006918. doi: 10.1002/14651858.CD006918.pub3.
7
Physical health care monitoring for people with serious mental illness.严重精神疾病患者的身体健康监测
Cochrane Database Syst Rev. 2014 Jan 17;2014(1):CD008298. doi: 10.1002/14651858.CD008298.pub3.

本文引用的文献

5
Aripiprazole for schizophrenia.阿立哌唑用于治疗精神分裂症。
Cochrane Database Syst Rev. 2006 Apr 19;2006(2):CD004578. doi: 10.1002/14651858.CD004578.pub3.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验